Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Petrelintide

INVESTIGATIONAL

Long-acting amylin analogue

5
graded results
0
ongoing records
4
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 1Very low evidence 4

Petrelintide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Subcutaneous injection; as of 2026-07-13. Zealand Pharma

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Petrelintide INVESTIGATIONAL
weight-loss Decrease
Very low evidence

Phase 1b: 6-week MAD gave ~5.3% and 5.1% weight loss at 0.6/1.2 mg weekly; 16-week MAD up to 8.6% mean vs 1.7% placebo, mild GI events. Phase 2b ZUPREME-1 (42 wk,...

Zealand Pharma phase 1b topline (GlobeNewswire June 2024); ZUPREME-1 phase 2b topline (Ze... Source
Full findingPhase 1b: 6-week MAD gave ~5.3% and 5.1% weight loss at 0.6/1.2 mg weekly; 16-week MAD up to 8.6% mean vs 1.7% placebo, mild GI events. Phase 2b ZUPREME-1 (42 wk, obesity/overweight without T2D) met its primary endpoint with up to 10.7% mean weight loss vs 1.7% placebo and 'placebo-like' GI tolerability.
Populationphase 1b MAD: healthy/overweight, 6 and 16 wk; ZUPREME-1: adults obesity/overweight without T2D, 42 wk
Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Petrelintide INVESTIGATIONAL
weight-loss Decrease
Very low evidence

Phase 1b MAD: dose-dependent weight loss over 16 weekly doses

Zealand Pharma topline press release, 20 Jun 2024 Source
PopulationOverweight/obese, median BMI 29, median age 49 (n=48), phase 1b MAD, 16 wk, RCT placebo-controlled
Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Petrelintide INVESTIGATIONAL
body-composition Not directional
Very low evidence

Positioned for high-quality weight loss with lean-mass preservation (company claim)

Zealand Pharma press release, 20 Jun 2024 Source
PopulationCompany positioning / preclinical
Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Petrelintide INVESTIGATIONAL
pharmacology Not directional
Low evidence

Long-acting amylin analogue / dual amylin-calcitonin receptor agonist (DACRA); used as reference scaffold for next-gen DACRA optimisation

Zong L et al. J Med Chem 2025;68:14907-14918 Source
PopulationMedicinal-chemistry / SAR (in-vitro + in-vivo)
Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)
ComparatorsBGM1812; natural amylin/calcitonin
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Petrelintide INVESTIGATIONAL
Stomach and gut No change
Very low evidence

Reported safe and well tolerated at all dose levels (company)

Zealand Pharma topline press release, 20 Jun 2024 Source
PopulationPhase 1b MAD (n=48), 16 wk
Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)
Comparatorsplacebo